Evaluation of Insulin Regimen and Glycemic Control in Noncritically Ill Hospitalized Patients with Type 2 Diabetes Receiving Continuous Enteral Nutrition Therapy

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2283-PUB
Author(s):  
DARYL J. SELEN ◽  
ALAN B. HOWARD ◽  
MATTHEW P. GILBERT
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Enteral Nutrition ◽  
Nutrition Therapy ◽  
Hospitalized Patients ◽  
Insulin Regimen

941-P: Frequency of Blood Glucose Monitoring in Relation to Medical Cost and Glycemic Control in Hospitalized Patients with Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 941-P
Author(s):  
LEI ZHANG ◽  
YAN GU ◽  
YUXIU YANG ◽  
NA WANG ◽  
WEIGUO GAO ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Glycemic Control ◽  
Medical Cost ◽  
Glucose Monitoring ◽  
Hospitalized Patients ◽  
Blood Glucose Monitoring

Effects of sliding scale insulin use on glycemic control and length of stay in hospitalized patients with Type 2 diabetes mellitus

Therapy ◽  
2004 ◽  
Vol 1 (1) ◽  
pp. 81-85 ◽  
Author(s):  
Samy I McFarlane ◽  
Fadi El-Atat ◽  
Jonathan Castro ◽  
John Shin ◽  
Linda Joseph ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Length Of Stay ◽  
Hospitalized Patients ◽  
Sliding Scale ◽  
Insulin Use

Changes in dietary intake improve glycemic control following a structured nutrition therapy during Ramadan in individuals with type 2 diabetes

2021 ◽  
Author(s):  
Barakatun-Nisak Mohd Yusof ◽  
Farah Yasmin Hasbullah ◽  
Aainaa Syarfa Mohd Shahar ◽  
Noraida Omar ◽  
Zalina Abu Zaid ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Dietary Intake ◽  
Nutrition Therapy

1270-P: Glycemic Control in Youth with Type 2 Diabetes Correlates with Weight Loss and Markers of Beta-Cell Function, but Not Intense Insulin Regimen

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1270-P
Author(s):  
LILY CHAO ◽  
MEIYU YEH ◽  
JENNIFER RAYMOND ◽  
JI HOON RYOO ◽  
NANCY T. CHANG
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Glycemic Control ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Insulin Regimen

scholarly journals Association between Diabetes Complications and the Triglyceride-Glucose Index in Hospitalized Patients with Type 2 Diabetes

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Ying Pan ◽  
Shao Zhong ◽  
Kaixin Zhou ◽  
Zijian Tian ◽  
Fei Chen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Diabetes Complications ◽  
Microvascular Complications ◽  
Hospitalized Patients ◽  
Poor Glycemic Control ◽  
Diabetic Patients ◽  
Tyg Index ◽  
Logistic Regressions

Background. Triglyceride-glucose (TyG) index is a convenient indicator of insulin resistance. It has been shown to be associated with macrovascular and microvascular complications in nonhospitalized diabetic patients. However, whether TyG index is a risk factor of diabetes vascular complications in hospitalized type 2 diabetic patients is unclear. We sought to explore the association between TyG index and the risk of macrovascular and microvascular complications in a large Chinese cohort of hospitalized patients. Method. A total of 4,721 patients with type 2 diabetes (T2D) who were hospitalized in the Department of Endocrinology, Kunshan Hospital Affiliated to Jiangsu University were enrolled between January 2015 and November 2020. TyG index was calculated as ln fasting   triglycerides   mg / dL × fasting   glucose   mg / dL / 2 . Measures of macrovascular complications included brachial-ankle pulse wave velocity (ba-PWV) and ankle-brachial index (ABI), whilst urine microalbumin (MAU), chronic kidney disease (CKD), and diabetic retinopathy (DR) were evaluated for microvascular complications. Logistic regressions were used to examine the association between TyG index and diabetes complications. Results. In univariate logistic regressions, higher TyG index was significantly ( p < 0.002 ) associated with increased odds of MAU ( OR = 1.39 , 95% CI: [1.22~1.59]) and ABI ( OR = 1.31 , 95% CI: [1.10-1.57]) but not CKD, DR, or ba-PWV. After controlling for confounders such as age, sex, and body mass index (BMI), TyG index remained strongly ( p < 0.002 ) associated with MAU and ABI. These associations were more pronounced ( p < 0.001 ) in patients with poor glycemic control or in the elderly. Conclusion. Hospitalized patients with an elevated TyG index were at a higher risk of lower limb vascular stenosis and nephric microvascular damage. Close monitoring of TyG index in patients with younger age or poor glycemic control could potentially reduce the burden of diabetes complications and prevent readmission.

scholarly journals Efficacy and safety of treatment with human insulin analogues in daily management of insulin naive patients with type 2 diabetes mellitus: results of multicenter 52-week observational study A1chive

2012 ◽  
Vol 15 (4) ◽  
pp. 115-121
Author(s):  
Marina Vladimirovna Shestakova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Observational Study ◽  
Human Insulin ◽  
Negative Influence ◽  
Insulin Analogues ◽  
Insulin Regimen

Modern insulin analogues allow safe improvement of glycemic control (not accompanied with increase in body mass or rate of severe hypoglycemic events) and its efficient maintenance during long period of time. In this paper we present results of multicenter 52-week prospective observational study A1chive (Russian cohort, n=9342), designed to assess safety and efficacy of treatment with human insulin analogues (Levemir?, NovoMix? 30 and NovoRapid? (Novo Nordisk) in daily management of insulin naive patients with type 2 diabetes mellitus. Prescription of human insulin analogues resulted in clinically and statistically significant improvement of glycemic control irrespective of initial insulin regimen. Therapy by various regimens (Levemir?, NovoMix? 30 or Levemir? + NovoRapid?) under conditions of daily clinical practice leads to marked improvement in glycemic control as measured by HbA1c (-2.9% in 12 month) with no evidence for negative influence on tolerability and short-term safety of the treatment. Furthermore, decrease in HbA1c levels was associated with pronounced and stable decrease in fasting and postprandial glucose levels (-5.0 mmol/L and -5.7 mmol/L, respectively). By the end of the follow-up all regimen groups reported improvement of QoL by treatment satisfaction criterion.

scholarly journals Cardiovascular Adverse Outcomes as Challenges on Glycemic Variability Among Patients with Type 2 Diabetes on Intensive Insulin Therapy: The Role of Medical Nutrition Therapy with Automatic Snacking

2021 ◽  
Vol 3 (2) ◽  
pp. 59-68
Author(s):  
Leilani B Mercado-Asis ◽  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Insulin Therapy ◽  
Intensive Insulin Therapy ◽  
Glycemic Variability ◽  
Nutrition Therapy ◽  
Medical Nutrition Therapy ◽  
Type 2 Dm ◽  
Medical Nutrition

The glycemic variability (GV) is the fluctuation of the blood glucose (BG) in relation to the daily mean BG or mean glycosylated hemoglobin (HbA1c). BG oscillations can be influenced by the type of food and timing of intake, activity, psychological condition (fear of hypoglycemia), and systemic hormonal cross-talking between insulin and glucagon. Pharmacologically, these BG oscillations can be affected by the regulators of insulin secretion like sulfonylurea and insulin. The increase in GV with very high and very low BG excursions has been associated with the development of macrovascular and microvascular complications among type 2 diabetes mellitus (DM) patients. Increased mortality has been demonstrated in the past among elderly patients on intensive insulin therapy due to severe hypoglycemia. Prompt intake of glucose has obviously compromised glycemic control and worsens the GV. Automatic snacking (AS) as a part of medical nutrition therapy (MNT) is the provision of snacks 2 h after meals which are taken even in the absence of hunger. This review will showcase our published papers among patients with type 2 DM where AS was instituted to obtain long-term glycemic control and prevent the occurrence of fatal postprandial hypoglycemia. Although, further research is needed, AS is a promising dietary management to address GV in type 2 DM patients on intensive insulin therapy.

Sign in / Sign up

Export Citation Format

Share Document